KEY POINTS
• MYXV binds human T lymphocytes but does not enter and infect T cells until after activation.
• MYXV-infected T lymphocytes proliferate less and secrete less inflammatory cytokines; but effectively deliver oncolytic virus to augment GVM.
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INTRODUCTION
Allogeneic hematopoietic cell transplant (allo-HCT) can be curative for patients with certain hematological malignancies. However, graft-versus-host disease (GVHD) remains a major challenge after allo-HCT. [1] [2] [3] An increasing number of experimental GVHD prophylaxis efforts have exploited T cell depletion strategies. [4] [5] [6] [7] Unfortunately, these approaches delay the time to donor engraftment, increase risk for disease relapse, and increase risk for opportunistic infections.
Recently, we discovered that ex vivo virotherapy with the oncolytic poxvirus, myxoma virus (MYXV), selectively targets malignant human hematopoietic cells like acute myeloid leukemia and multiple myeloma, while sparing normal human hematopoietic stem and progenitor cells. [8] [9] [10] MYXV is a viral oncolytic agent that is non-pathogenic to humans and mice but has natural tropism for a variety of human cancers. [11] [12] [13] In the course of developing MYXV as an ex vivo purging agent for transplant, we serendipitously discovered that NSG mice receiving human HCT xenografts treated ex vivo with MYXV developed no GVHD, lived longer, and yet still exhibited robust human hematopoietic engraftment in the recipient bone marrow. 14 We hypothesized that MYXV impaired the GVHD capacity of alloreactive donor T lymphocytes. To test this prediction and dissect mechanisms by which MYXV suppresses GVHD, we focused on human T lymphocyte responses after MYXV exposure.
METHODS

Virus Binding and Infection Conditions
MYXV virion binding to cells was carried out by incubating resting human T cells with vMyx-Venus/M093L at a multiplicity of infection (MOI) of 10 for one hour on ice. 15 MYXV infections were performed by incubating human resting or activated T cells with vMyx-GFP 16 or vMyx-GFP/TrFP 17 at MOI=10 for 1 hour at room temperature. For both binding and infection, mock-treated cells were incubated in complete media containing no virus under the same incubation conditions. Furthermore, heat-and UV-inactivated vMyx-GFP were used as controls to assess if virus replication competency is needed for the inhibition of T cell proliferation (see Supplemental Methods for details).
Proliferation Analysis and One-Way Mixed Lymphocyte Reaction (MLR) Assays
Isolated human CD3 + T cells were first labeled using the CellTrace TM violet (CTV) cell proliferation kit (Invitrogen), as per manufacturer's recommendations (see Supplemental Methods for details). Next, T cells were either mock-treated, or infected with vMyx-GFP (MOI=10), and plated in 96-well round-bottomed plate. Then, cells were either stimulated (i.e., by adding α-CD3/α-CD28 coated microbeads) or left unstimulated. Cells were cultured in a humidified chamber at 37 o C and 5% CO 2 , during 72 or 96 hours.
Proliferation of T cells was evaluated using flow cytometry (see Supplemental Methods
for details). One-way mixed lymphocyte reaction (MLR) assays were performed using mononuclear cells (MNCs) derived from PBMCs or cord blood (CB) from healthy donors (see Supplemental Methods for details).
18, 19
Graft-versus-Malignancy Assays
Mock-treated or MYXV-treated T lymphocytes (either unstimulated or anti-CD3/CD28 activated) were cultured for 48 hours at 37 o C, 5% CO 2 . At this point, the human multiple
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RESULTS
Myxoma Virus Binds to Human T Lymphocytes but Stimulation of T Lymphocytes Is Required for Productive Infection
Our first question was whether MYXV can bind or infect resting human T lymphocytes.
Primary human CD3 + T cells, isolated from healthy donor peripheral blood, were incubated with fluorescently labeled MYXV (vMyx-Venus/M093L 15 ) for one hour. After one hour adsorption, the T cells were washed of free virus and then analyzed by flow cytometry for evidence of MXYV binding. The T lymphocytes showed Venus-tagged MYXV binding ( Figure 1A ), ranging from 13.00% to 62.93% that varied by donor (Supplemental Table 1 ). Since the lower limit of sensitivity of this binding assay with Venus-tagged MYXV is approximately 500 virus particles per cell, these binding percentages are likely underestimations of the actual percentage of T lymphocytes with bound MYXV.
We next questioned whether MYXV actively infects these human T lymphocytes using a vMyx-GFP that expresses GFP encoded in the viral genome and driven by a synthetic early/late viral promoter, so that the very earliest stages of virus replication can be monitored by the expression of GFP. When human T lymphocytes were in an unstimulated state, MYXV initiated its infection cycle in only a very small fraction of the T cells by 72 or 96 hours after incubation ( Figure 1B , middle panels). In contrast, upon
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From stimulation of T cells with α-CD3/α-CD28 beads, the GFP-tagged MYXV infected the activated T cells at much higher levels (GFP + ) ( Figure 1B , lower panels). Together, these data show that MYXV binds resting human T cells, but enters and initiates infection only after T cell activation. In contrast, in the absence of stimulation, there is a very early block in MYXV replication prior to early viral gene expression. Importantly, nearly 100% of the activated T cells became infected with GFP-tagged MYXV ( Figure   1C ), confirming that some input virus was initially bound to essentially all of the available T cells in the culture, regardless of whether the donor exhibited high (50-60%) or low (10-20%) binding levels of input Venus-tagged virus.
These results were confirmed with flow cytometric analysis. In all cases, after 72 hours, MYXV successfully infected over 90% of stimulated T cells ( Figure 1E ) as compared to unstimulated T cells ( Figure 1D Table 2 ). Thus, we observe no particular bias amongst the various subclasses of CD3 + T lymphocytes, in terms of their ability to become infected by MYXV following cell activation with anti-CD3/CD28.
MYXV Replication Generates Low Levels of Progeny Virus in Stimulated Human T Lymphocytes
To determine whether the viral replication cycle was completed with the concomitant production of new infectious progeny virus, we performed single step viral growth analysis ( Figure 1H ). To do this, unstimulated or stimulated T cells were incubated with MYXV, washed, sampled at serial time points, pelleted and harvested. The infectious 
Inhibition of Activation-Induced T Lymphocyte Proliferation by MYXV Infection
We next analyzed the impact of this infection on lymphocyte proliferation in response to the T cell activation signals. As expected, unstimulated donor human T lymphocytes, whether mock-treated or MYXV-treated, showed no proliferation after 72 hours or 96 hours in culture (Figure 2A, 2C ). Stimulated T cells that were mock-treated showed the expected increase in cell proliferation at 72 and 96 hours ( Figure 2B , red histograms).
But, when stimulated T cells were MYXV-treated, two different proliferation patterns
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Some normal donors, however, were classified as "partial responders" because MYXV decreased but did not fully suppress the proliferation of stimulated T cells ( Figure 2D Figure 2) . Together, the results indicate a preferential attenuation of Th1 polarization and Th17, with relatively low attenuation of Th2, and Treg differentiation.
MYXV Infection of Activated Human T Cells Affects Viability
MYXV infection plus stimulation with anti-CD3/CD28 beads resulted in increased percentage of non-viable T lymphocytes for all donors tested ( Figure 3 ). Specifically, this additive effect was observed in T cell samples from either full responders ( Figure 3A and 3B) or from partial responders ( Figure 3C and 3D), suggesting that such augmented decline in T cell viability is donor independent ( Figure 3E and 3F). Even though a slightly higher frequency of cell death was observed as a trend for full responders vs. partial responders infected with MYXV and stimulated with α-CD3/α-CD28 beads, it was not statistically significant (i.e., at 72 hours after culturing: 30.00 ± 8.73% full responders vs.
19.59 ± 1.60% partial responders, P = 0.32; and at 96 h after culturing: 49.54 ± 8.01% full responders vs. 37.73 ± 7.14% partial responders, P = 0.12). On the other hand, unstimulated T cells mock-treated or MYXV-treated, exhibited low and very similar frequencies of cell death ( Figure 3E and 3F).
MYXV Infection of Stimulated Human T Lymphocytes Downregulates a Subset of
Activation-Inducible Cytokines
Excessive levels of IL-2 have been implicated in the pathophysiology of acute GVHD. Table 4 ).
Besides IL-2, other lymphocyte-derived cytokines involved in GVHD include interleukin-4
(IL-4), inteleukin-10 (IL-10) and interferon-gamma (IFN-). [22] [23] [24] Of these cytokines, only activation-induced soluble IFN-was significantly decreased after MYXV infection as compared to mock-treated and stimulated samples ( Figure 4 ). Notably, we observed a similar inhibitory pattern for T cells derived from both types of donors at 72 hours ( Figure   4J ) and at 96 hours ( Figure 4K ). Intracellular staining of IFN-confirmed these findings (Supplemental Table 5 ).
Infection with MYXV Decreases the Proliferation and Cytokine Production of Allo-
Stimulated T cells
We next used mixed lymphocyte reactions to recapitulate allo-stimulation conditions in pattern and cytokine production no major differences were found for PBMCs or CB cells, suggesting that both PBMCs and CB are almost equally susceptible to MYXV.
Activated T Lymphocytes Efficiently Transfer MYXV and Kill Susceptible Cancer Cells
The purpose of allo-HCT is two-fold: (1) to replace the hematopoietic system of the recipient using hematopoietic stem/progenitor cells from a closely matched donor, and (2) to attack and eliminate residual cancer cells in the recipient by means of alloreactive donor T cells. Any viable adjunct therapy to allo-HCT to prevent GVHD should not come at the price of either reducing engraftment of the normal stem cells or reducing the efficiency of GVM. Previously, when we used a xenograft model of human multiple myeloma (MM) in immunodeficient mice, we found that ex vivo treatment of the donor human bone marrow with MYXV, while leaving normal stem cell engraftment unaffected, not only prevented GVHD but also preserved GVM against pre-seeded myeloma. 14 However, the mechanisms of GVM after MYXV treatment of the donor transplant were unknown in our prior study. Therefore, we designed in vitro modeling experiments to examine the mechanistic basis for the observed GVM preservation ( Figure 7A) . Briefly, We previously demonstrated efficient human hematopoietic engraftment with no GVHD after xenotransplant of MYXV-treated primary human hematopoietic stem/progenitor cells. 14 The safety of using MYXV with human hematopoietic stem/progenitor cells has been correlated to the virus' inability to bind or infect normal human CD34 The data in this report are the first to reveal mechanisms by which ex vivo virotherapy with MYXV controls GVHD yet does not compromise GVM.
14 Herein, we present direct evidence that MYXV binds unstimulated human CD3 + T lymphocytes but T cell activation is required to initiate productive virus infection, which can then be delivered to susceptible cancer cells.
In addition to efficiently infecting stimulated human T lymphocytes from all normal donors tested, MYXV also impaired T cell functionality by (1) reducing T cell proliferation and (2) down-regulating T cell signaling pathways of known importance in GVHD. antibodies against CD3, CD4 and CD8, and the levels of GFP + in each population were quantified by using flow cytometry. Likewise (G), levels of infection of T lymphocyte activation proteins CD25 and CD69 were also quantified using flow cytometry. Data reported are representative of al least six independent experiments. Significance (i.e., P < 0.05) was determined using the Student's t-test. To investigate whether MYXV launches productive virus replication in stimulated human T lymphocytes we performed 
Functional characterization of alloreactive T cells identifies CD25 and CD71 as
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